WINT — Windtree Therapeutics Share Price
0.000.00%
Last trade - 00:00- $1.90m
- -$0.65m
- 12
- 58
- 12
- 17
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.12 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -25.05% | ||
| Return on Equity | -53.1% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.2 | n/a | n/a | n/a | n/a | n/a | 12.2 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, pre-clinical SERCA2a activators for heart failure and VAR-101 and VAR-102, pre-clinical precision atypical protein kinase C iota (aPKCi) inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum, enhancing calcium reuptake from the cytoplasm. It also has a licensing business model with partnership out-licenses in place.
Directors
- James Huang NEC (56)
- Craig Fraser PRE (56)
- John Hamill CFO (56)
- Eric Curtis COO (53)
- Joseph Soffer EVP
- Diane Carman SVP
- Steven Simonson SVP (62)
- Randall White VPR
- Daniel Geffken IND (64)
- Evan Loh IND (62)
- Robert Scott IND (67)
- Leslie Williams IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- November 6th, 1992
- Public Since
- August 9th, 1995
- No. of Shareholders
- 38
- No. of Employees
- 15
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 591,909
- Address
- 2600 Kelly Rd Ste 100, WARRINGTON, 18976-3652
- Web
- https://windtreetx.com/
- Phone
- +1 2154889300
- Auditors
- EisnerAmper LLP
Upcoming Events for WINT
Windtree Therapeutics Inc Annual Shareholders Meeting
Q3 2024 Windtree Therapeutics Inc Earnings Release
Similar to WINT
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Windtree Therapeutics share price?
As of Today at 24:10 UTC, shares in Windtree Therapeutics are trading at $3.14. This share price information is delayed by 15 minutes.
How has the Windtree Therapeutics share price performed this year?
Shares in Windtree Therapeutics last closed at $3.14 and the price had moved by -86.37% over the past 365 days. In terms of relative price strength the Windtree Therapeutics share price has underperformed the S&P500 Index by -89.16% over the past year.
What are the analyst and broker recommendations for Windtree Therapeutics?
The overall consensus recommendation for Windtree Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Windtree Therapeutics dividend yield?
Windtree Therapeutics does not currently pay a dividend.
Does Windtree Therapeutics pay a dividend?
Windtree Therapeutics does not currently pay a dividend.
When does Windtree Therapeutics next pay dividends?
Windtree Therapeutics does not currently pay a dividend.
How do I buy Windtree Therapeutics shares?
To buy shares in Windtree Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Windtree Therapeutics?
As of the previous close price of $3.14, shares in Windtree Therapeutics had a market capitalisation of $1.86m.
Where are Windtree Therapeutics shares listed?
Here are the trading details for Windtree Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: WINT
What kind of share is Windtree Therapeutics?
Based on an overall assessment of its quality, value and momentum Windtree Therapeutics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Windtree Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Windtree Therapeutics is $1.00. That is 68.15% below the last closing price of $3.14.
Analysts covering Windtree Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.97 for the next financial year.
What is the trend in the Windtree Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Windtree Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -79.12%.
As of the last closing price of $3.14, shares in Windtree Therapeutics were trading -71.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Windtree Therapeutics PE Ratio?
The Windtree Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Windtree Therapeutics?
Windtree Therapeutics' management team is headed by:
- James Huang - NEC
- Craig Fraser - PRE
- John Hamill - CFO
- Eric Curtis - COO
- Joseph Soffer - EVP
- Diane Carman - SVP
- Steven Simonson - SVP
- Randall White - VPR
- Daniel Geffken - IND
- Evan Loh - IND
- Robert Scott - IND
- Leslie Williams - IND